The analysis showed that the definitively deleterious BARD1 mutation is associated with low/moderate BC risk (OR ~2) and that the risk is further increased in the group of patients with a risk for heritable BC (OR ~3), including TNBC, bilateral BC, early diagnosis of BC, and familial BC/OC. Here, BARD1 is linked to breast cancer.